These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 1974569)

  • 1. Long-term survival of adoptively transferred tumor-infiltrating lymphocytes in mice.
    Alexander RB; Rosenberg SA
    J Immunol; 1990 Sep; 145(5):1615-20. PubMed ID: 1974569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic characterization of murine tumor-infiltrating T lymphocytes.
    Karpati RM; Banks SM; Malissen B; Rosenberg SA; Sheard MA; Weber JS; Hodes RJ
    J Immunol; 1991 Mar; 146(6):2043-51. PubMed ID: 1672340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine (IFN-gamma and granulocyte/macrophage colony-stimulating factor) producing donor tumor-infiltrating lymphocytes.
    Nagoshi M; Goedegebuure PS; Burger UL; Sadanaga N; Chang MP; Eberlein TJ
    J Immunol; 1998 Jan; 160(1):334-44. PubMed ID: 9551989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Murine studies using polyethylene glycol-modified recombinant human interleukin 2 (PEG-IL-2): antitumor effects of PEG-IL2 alone and in combination with adoptive cellular transfer.
    Yang JC; Schwarz SL; Perry-Lalley DM; Rosenberg SA
    Lymphokine Cytokine Res; 1991 Dec; 10(6):475-80. PubMed ID: 1804310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
    Wallace PK; Palmer LD; Perry-Lalley D; Bolton ES; Alexander RB; Horan PK; Yang JC; Muirhead KA
    Cancer Res; 1993 May; 53(10 Suppl):2358-67. PubMed ID: 8485722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The therapeutic efficacy of murine anti-tumor T cells: freshly isolated T cells are more therapeutic than T cells expanded in vitro.
    Evans R; Kamdar SJ; Duffy TM; Krupke DM; Fuller JA; Dudley ME
    Anticancer Res; 1995; 15(2):441-7. PubMed ID: 7763019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor T cells can be induced to grow and survive long term in vivo without previous host immunosuppression.
    Chen W; Cheever MA
    J Immunol; 1994 May; 152(10):4767-74. PubMed ID: 8176202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental allergic encephalomyelitis. T cell trafficking to the central nervous system in a resistant Thy-1 congenic mouse strain.
    Skundric DS; Huston K; Shaw M; Tse HY; Raine CS
    Lab Invest; 1994 Nov; 71(5):671-9. PubMed ID: 7526038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.
    Schultz KR; Klarnet JP; Peace DJ; Cheever MA; Badger CC; Bernstein ID; Greenberg PD
    Cancer Res; 1990 Sep; 50(17):5421-5. PubMed ID: 2386946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma.
    Chou T; Shu S
    J Immunol; 1987 Sep; 139(6):2103-9. PubMed ID: 2957448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
    Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA
    J Immunol; 1985 Nov; 135(5):3623-35. PubMed ID: 3900213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-2 activated microglia engulf tumor infiltrating T cells in the central nervous system.
    Tamakawa N; Saio M; Suwa T; Ohe N; Yoshimura S; Iwama T; Shinoda J; Sakai N; Takami T
    Int J Mol Med; 2004 Apr; 13(4):497-503. PubMed ID: 15010848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures.
    Topalian SL; Kasid A; Rosenberg SA
    J Immunol; 1990 Jun; 144(11):4487-95. PubMed ID: 2160503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An improved method for growing murine tumor-infiltrating lymphocytes with in vivo antitumor activity.
    Yang JC; Perry-Lalley D; Rosenberg SA
    J Biol Response Mod; 1990 Apr; 9(2):149-59. PubMed ID: 1971302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumor gene expression after adoptive immunotherapy in a murine tumor model. Regulation of messenger RNA levels associated with the differential expansion of tumor-infiltrating lymphocytes.
    Evans R; Kamdar SJ; Duffy T; Edison L
    J Immunol; 1993 Jan; 150(1):177-84. PubMed ID: 8417123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptively transferred antigen-specific T cells can be grown and maintained in large numbers in vivo for extended periods of time by intermittent restimulation with specific antigen plus IL-2.
    Chen W; Reese VA; Cheever MA
    J Immunol; 1990 May; 144(10):3659-66. PubMed ID: 2332628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2.
    Spiess PJ; Yang JC; Rosenberg SA
    J Natl Cancer Inst; 1987 Nov; 79(5):1067-75. PubMed ID: 3500355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solid-phase anti-CD3 antibody activation of murine tumor-infiltrating lymphocytes.
    Massaro AF; Schoof DD; Rubinstein A; Zuber M; Leonard-Vidal FJ; Eberlein TJ
    Cancer Res; 1990 May; 50(9):2587-92. PubMed ID: 2139356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.